Within the last year
Within the past 3 years
1 - 10 of 45 articles
Background. Patients with end‐stage renal disease have an increased risk of developing coronary artery disease (CAD). The cardiovascular mortality of dialysis patients is 10–15 times higher compared with the general population. The aim of our study was to evaluate the morphological...
Background. The objectives of the present trial were to compare the efficacy and safety of two i.v. iron preparations with respect to haemoglobin levels, iron status and recombinant human erythropoetin (rHuEpo) dosage requirements in stable, rHuEpo‐treated haemodialysis patients (maintenance...
Background. Chronic renal failure (CRF) is associated with an increased risk of ischaemic heart disease (IHD), but the mechanisms responsible are controversial. We investigated the relationship of two sets of candidate mechanisms—indices of LDL oxidation and markers of inflammatory...
Background. Vasopeptidase inhibition (VPI) represents a new therapeutic principle including both inhibition of angiotensin‐converting enzyme (ACE) and neutral endopeptidase (NEP). The present study investigated the effect of the vasopeptidase inhibitor omapatrilat on endothelin‐1...
Background. The proliferation of glomerular epithelial cells (GEC) is usually observed in crescentic glomerulonephritis. However, the regulation of GEC proliferation is not fully understood. Although it is known that interleukin‐1 β (IL‐1 β ) has a mitogenic effect on mesangial cells and is...
Background. During haemodialysis the blood‐membrane contact causes a release of platelet granule content, which contains platelet‐derived growth factor AB (PDGF‐AB). In view of the potential role of this in altering biocompatibility during haemodialysis, we evaluated the intra‐ and...
Background. The new cyclosporin (CsA) formulation, Neoral ® , has different pharmacokinetics compared with Sandimmune ® (SIM). Larger area under the curve (AUC) values with equivalent trough blood values are reached when Neoral is administered at equivalent doses to SIM. Previously, we showed a...
Read and print from thousands of top scholarly journals.
Sign up with Facebook
Sign up with Google
Already have an account? Log in
Save this article to read later. You can see your Read Later on your DeepDyve homepage.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.